PDK4 and hepatocellular carcinoma: Consistently, dual inhibition of LDHA, which blocks glycolysis end-step, and pyruvate dehydrogenase kinase 4 (PDK4), which favors the flow of pyruvate into the TCA cycle, represses the CSC phenotype in CD133+/PLC/PRF/5 hepatocellular carcinoma (HCC) cells [55].